{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:23:23Z","timestamp":1761092603916,"version":"build-2065373602"},"reference-count":85,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s12350-018-01470-5","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T14:21:49Z","timestamp":1542291709000},"page":"2159-2167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardio-oncology: Understanding cardiotoxicity to guide patient focused imaging"],"prefix":"10.1016","volume":"25","author":[{"suffix":"III","given":"Raymond","family":"Russell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s12350-018-01470-5_bib1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention","volume":"102","author":"Albini","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1007\/s12350-018-01470-5_bib2","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-018-01470-5_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000665","article-title":"Cancer therapy-induced cardiotoxicity: Basic mechanisms and potential cardioprotective therapies","volume":"3","author":"Hahn","year":"2014","journal-title":"J Am Heart Assoc."},{"key":"10.1007\/s12350-018-01470-5_bib4","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s12350-016-0538-8","article-title":"The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy","volume":"23","author":"Russell","year":"2016","journal-title":"J Nucl Cardiol."},{"key":"10.1007\/s12350-018-01470-5_bib5","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10549-006-9413-7","article-title":"Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer","volume":"104","author":"Abu-Khalaf","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1007\/s12350-018-01470-5_bib6","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1161\/CIRCULATIONAHA.116.023463","article-title":"Detailed echocardiographic phenotyping in breast cancer patients: Associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of followup","volume":"135","author":"Narayan","year":"2017","journal-title":"Circulation"},{"key":"10.1007\/s12350-018-01470-5_bib7","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circul Cardiovas Imaging"},{"key":"10.1007\/s12350-018-01470-5_bib8","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1011196910325","volume":"12","author":"Dazzi","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1007\/s12350-018-01470-5_bib9","doi-asserted-by":"crossref","unstructured":"Steinberg JS, Cohen AJ, Wasserman AG, Cohen P, Ross AM. Acute arrhythmogenicity of doxorubicin administration. Cancer 1987;60:1213\u20131218. 10.1002\/1097-0142(19870915)60:6<1213::AID-CNCR2820600609>3.0.CO;2-V, 3621107","DOI":"10.1002\/1097-0142(19870915)60:6<1213::AID-CNCR2820600609>3.0.CO;2-V"},{"key":"10.1007\/s12350-018-01470-5_bib10","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/0002-9343(78)90802-1","article-title":"Early anthracycline cardiotoxicity","volume":"65","author":"Bristow","year":"1978","journal-title":"Am J Med"},{"key":"10.1007\/s12350-018-01470-5_bib11","first-page":"124","article-title":"Takotsubo cardiomyopathy following initial chemotherapy presenting with syncope and cardiogenic shock: A case report and literature review","volume":"2","author":"Fernandez","year":"2001","journal-title":"J Clin Exp Cardiol."},{"key":"10.1007\/s12350-018-01470-5_bib12","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJM200506093522321","article-title":"Acute doxorubicin cardiotoxicity","volume":"352","author":"Hayek","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1007\/s12350-018-01470-5_bib13","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1007\/s12350-018-01470-5_bib14","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1007\/s12350-018-01470-5_bib15","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","article-title":"Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes\u2014A report from the Children\u2019s Oncology Group","volume":"30","author":"Blanco","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1007\/s12350-018-01470-5_bib16","doi-asserted-by":"crossref","first-page":"b4606","DOI":"10.1136\/bmj.b4606","article-title":"Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort","volume":"339","author":"Mulrooney","year":"2009","journal-title":"BMJ"},{"key":"10.1007\/s12350-018-01470-5_bib17","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"10.1007\/s12350-018-01470-5_bib18","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: Prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Curr Cardiol Rev."},{"key":"10.1007\/s12350-018-01470-5_bib19","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1016\/S0021-9258(17)35746-0","article-title":"Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase","volume":"261","author":"Davies","year":"1986","journal-title":"J Biol Chem."},{"key":"10.1007\/s12350-018-01470-5_bib20","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1016\/S0021-9258(17)35747-2","article-title":"Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical","volume":"261","author":"Doroshow","year":"1986","journal-title":"J Biol Chem."},{"key":"10.1007\/s12350-018-01470-5_bib21","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0076-6879(04)78025-8","article-title":"Doxorubicin cardiotoxicity and the control of iron metabolism: Quinone-dependent and independent mechanisms","volume":"378","author":"Minotti","year":"2004","journal-title":"Methods Enzymol"},{"key":"10.1007\/s12350-018-01470-5_bib22","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1200\/JCO.1997.15.4.1333","article-title":"Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy","volume":"15","author":"Swain","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1007\/s12350-018-01470-5_bib23","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer","volume":"15","author":"Swain","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1007\/s12350-018-01470-5_bib24","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"key":"10.1007\/s12350-018-01470-5_bib25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0076-6879(04)78026-X","article-title":"Oxidant-induced iron signaling in Doxorubicin-mediated apoptosis","volume":"378","author":"Kotamraju","year":"2004","journal-title":"Methods Enzymol"},{"key":"10.1007\/s12350-018-01470-5_bib26","first-page":"4592","article-title":"Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: Bax ratio","volume":"62","author":"Childs","year":"2002","journal-title":"Can Res"},{"key":"10.1007\/s12350-018-01470-5_bib27","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/0002-9343(87)90212-9","article-title":"Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: Seven-year experience using serial radionuclide angiocardiography","volume":"82","author":"Schwartz","year":"1987","journal-title":"Am J Med."},{"key":"10.1007\/s12350-018-01470-5_bib28","first-page":"842","article-title":"Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats","volume":"45","author":"Bennink","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1007\/s12350-018-01470-5_bib29","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2967\/jnumed.110.082784","article-title":"Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity","volume":"52","author":"de Geus-Oei","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1007\/s12350-018-01470-5_bib30","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12350-013-9707-1","article-title":"Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively","volume":"20","author":"Schwartz","year":"2013","journal-title":"J Nucl Cardiol."},{"key":"10.1007\/s12350-018-01470-5_bib31","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-018-01470-5_bib32","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.amjcard.2011.01.006","article-title":"Early detection and prediction of cardiotoxicity in chemotherapy-treated patients","volume":"107","author":"Sawaya","year":"2011","journal-title":"Am J Cardiol."},{"key":"10.1007\/s12350-018-01470-5_bib33","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: Clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1007\/s12350-018-01470-5_bib34","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"10.1007\/s12350-018-01470-5_bib35","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/annonc\/mdf170","article-title":"Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy","volume":"13","author":"Cardinale","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1007\/s12350-018-01470-5_bib36","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-018-01470-5_bib37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2008.17.2627","article-title":"American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants","volume":"27","author":"Hensley","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1007\/s12350-018-01470-5_bib38","first-page":"CD003917","article-title":"Cardioprotective interventions for cancer patients receiving anthracyclines","volume":"6","author":"van Dalen","year":"2011","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1007\/s12350-018-01470-5_bib39","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"10.1007\/s12350-018-01470-5_bib40","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-018-01470-5_bib41","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-018-01470-5_bib42","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1007\/s12350-018-01470-5_bib43","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1007\/s12350-018-01470-5_bib44","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial","volume":"25","author":"Suter","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1007\/s12350-018-01470-5_bib45","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1007\/s12350-018-01470-5_bib46","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/heartjnl-2012-303151","article-title":"Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors","volume":"99","author":"Farolfi","year":"2013","journal-title":"Heart"},{"key":"10.1007\/s12350-018-01470-5_bib47","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.addr.2006.05.003","article-title":"Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study","volume":"58","author":"Pegram","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1007\/s12350-018-01470-5_bib48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/sonc.2002.34051","article-title":"Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study","volume":"29","author":"Schneider","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1007\/s12350-018-01470-5_bib49","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/378394a0","article-title":"Requirement for neuregulin receptor erbB2 in neural and cardiac development","volume":"378","author":"Lee","year":"1995","journal-title":"Nature"},{"key":"10.1007\/s12350-018-01470-5_bib50","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1161\/CIRCULATIONAHA.110.991125","article-title":"Endothelium-derived neuregulin protects the heart against ischemic injury","volume":"123","author":"Hedhli","year":"2011","journal-title":"Circulation"},{"key":"10.1007\/s12350-018-01470-5_bib51","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1096\/fj.08-129072","article-title":"Metalloproteinase-dependent cleavage of neuregulin and autocrine stimulation of vascular endothelial cells","volume":"24","author":"Kalinowski","year":"2010","journal-title":"Faseb J."},{"key":"10.1007\/s12350-018-01470-5_bib52","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/cvr\/cvr352","article-title":"Endothelial-derived neuregulin is an important mediator of ischaemia-induced angiogenesis and arteriogenesis","volume":"93","author":"Hedhli","year":"2012","journal-title":"Cardiovasc Res"},{"key":"10.1007\/s12350-018-01470-5_bib53","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mds328","article-title":"Pertuzumab: new hope for patients with HER2-positive breast cancer","volume":"24","author":"Capelan","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1007\/s12350-018-01470-5_bib54","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/annonc\/mdr294","article-title":"Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab","volume":"23","author":"Lenihan","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1007\/s12350-018-01470-5_bib55","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1007\/s12350-018-01470-5_bib56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1007\/s12350-018-01470-5_bib57","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0025-6196(11)60896-3","article-title":"Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials","volume":"83","author":"Perez","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1007\/s12350-018-01470-5_bib58","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"10.1007\/s12350-018-01470-5_bib59","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s40261-014-0222-1","article-title":"Bevacizumab increases the risk of severe congestive heart failure in cancer patients: An up-to-date meta-analysis with a focus on different subgroups","volume":"34","author":"Qi","year":"2014","journal-title":"Clin Drug Investig."},{"key":"10.1007\/s12350-018-01470-5_bib60","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/CMAR.S77400","article-title":"Cancer therapy and cardiovascular risk: Focus on bevacizumab","volume":"7","author":"Economopoulou","year":"2015","journal-title":"Cancer Manag Res."},{"key":"10.1007\/s12350-018-01470-5_bib61","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1007\/s12350-018-01470-5_bib62","doi-asserted-by":"crossref","first-page":"e92146","DOI":"10.1371\/journal.pone.0092146","article-title":"Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use","volume":"9","author":"Uitdehaag","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1007\/s12350-018-01470-5_bib63","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"48","key":"10.1007\/s12350-018-01470-5_bib64","doi-asserted-by":"crossref","first-page":"18895","DOI":"10.1073\/pnas.0810246105","article-title":"Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice","volume":"105","author":"Louvet","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1007\/s12350-018-01470-5_bib65","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/01.ATV.0000124105.39900.db","article-title":"Imatinib attenuates diabetes-associated atherosclerosis","volume":"24","author":"Lassila","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1007\/s12350-018-01470-5_bib66","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"10.1007\/s12350-018-01470-5_bib67","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"Le Coutre","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1007\/s12350-018-01470-5_bib68","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1007\/s12350-018-01470-5_bib69","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: A retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"10.1007\/s12350-018-01470-5_bib70","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1016\/S2352-3026(15)00127-1","article-title":"Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: A phase 2 study","volume":"2","author":"Jain","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1007\/s12350-018-01470-5_bib71","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1007\/s12350-018-01470-5_bib72","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/eurheartj\/eht114","article-title":"Cardiovascular complications of radiation therapy for thoracic malignancies: The role for non-invasive imaging for detection of cardiovascular disease","volume":"35","author":"Groarke","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1007\/s12350-018-01470-5_bib73","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.2012.43.0702","article-title":"Increased tricuspid regurgitant jet velocity by Doppler echocardiography in adult survivors of childhood cancer: A report from the St Jude Lifetime Cohort Study","volume":"31","author":"Armstrong","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1007\/s12350-018-01470-5_bib74","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1007\/s12350-018-01470-5_bib75","first-page":"1756","article-title":"The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer","volume":"47","author":"Gayed","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1007\/s12350-018-01470-5_bib76","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijrobp.2005.01.029","article-title":"The incidence and functional consequences of RT-associated cardiac perfusion defects","volume":"63","author":"Marks","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1007\/s12350-018-01470-5_bib77","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JTO.0b013e3181990c46","article-title":"Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer","volume":"4","author":"Gayed","year":"2009","journal-title":"J Thorac Oncol."},{"key":"10.1007\/s12350-018-01470-5_bib78","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0167-8140(02)00133-0","article-title":"Detection of defects in myocardial perfusion imaging in patients with early breast cancer treated with radiotherapy","volume":"64","author":"Seddon","year":"2002","journal-title":"Radiother Oncol"},{"key":"10.1007\/s12350-018-01470-5_bib79","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2006.08.6595","article-title":"Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer","volume":"25","author":"Correa","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1007\/s12350-018-01470-5_bib80","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1200\/JCO.2013.49.3205","article-title":"Modifiable risk factors and major cardiac events among adult survivors of childhood cancer","volume":"31","author":"Armstrong","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1007\/s12350-018-01470-5_bib81","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ijrobp.2015.07.2292","article-title":"Exposure of the heart in breast cancer radiation therapy: A systematic review of heart doses published during 2003\u20132013","volume":"93","author":"Taylor","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1007\/s12350-018-01470-5_bib82","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.radonc.2004.03.012","article-title":"Breathing adapted radiotherapy of breast cancer: Reduction of cardiac and pulmonary doses using voluntary inspiration breath-hold","volume":"72","author":"Pedersen","year":"2004","journal-title":"Radiother Oncol"},{"key":"10.1007\/s12350-018-01470-5_bib83","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1515\/raon-2018-0008","article-title":"Voluntary deep inspiration breath-hold reduces the heart dose without compromising the target volume coverage during radiotherapy for left-sided breast cancer","volume":"52","author":"Al-Hammadi","year":"2018","journal-title":"Radiol Oncol."},{"key":"10.1007\/s12350-018-01470-5_bib84","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ctrv.2017.11.006","article-title":"Proton therapy for locally advanced breast cancer: A systematic review of the literature","volume":"63","author":"Kammerer","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1007\/s12350-018-01470-5_bib85","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.radonc.2014.04.009","article-title":"Cardiac dose sparing and avoidance techniques in breast cancer radiotherapy","volume":"112","author":"Shah","year":"2014","journal-title":"Radiother Oncol"}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12350-018-01470-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-018-01470-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107135812302490X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107135812302490X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-018-01470-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:04:29Z","timestamp":1761026669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107135812302490X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":85,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S107135812302490X"],"URL":"https:\/\/doi.org\/10.1007\/s12350-018-01470-5","relation":{},"ISSN":["1071-3581"],"issn-type":[{"type":"print","value":"1071-3581"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardio-oncology: Understanding cardiotoxicity to guide patient focused imaging","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s12350-018-01470-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 American Society of Nuclear Cardiology. Published by ELSEVIER INC. All rights reserved. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}